EMILY BALINT: Open Payments
NPI 1982003018 · NEPTUNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$466 in 25 payments from 10 companies in 2025. Trend: 2023 $503 · 2024 $671 · 2025 $466
Food & beverage: $466
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 8 | $163 |
| Neurocrine BioSciences, Inc. | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 3 | $46 |
| Bausch Health US, LLC | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Lilly USA, LLC | 1 | $24 |
| Alkermes, Inc. | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
Products named: INVEGA SUSTENNA, INGREZZA, SPRAVATO, FANAPT, WELLBUTRIN, AUSTEDO XR, Jornay PM, AMYVID.
Industry payments across NJ — which companies pay providers there.
